Q2 2026 *Results*

We delivered double-digit sales growth and strong business EPS growth in the second quarter and, looking ahead, we are confident in our trajectory of profitable growth. Our strong financial foundation is expected to support continued pipeline enhancement and external growth opportunities in the years ahead.

Belén Garijo
Chief Executive Officer

Q2 2026 company sales

€11.6 bn
+17.8% at constant exchange rates
+16.0% on a reported basis

Q2 2026 business earnings per share

€2.09
+33.3% at constant exchange rates
+31.4% on a reported basis

Sales by Category

Dupixent	Pharma launches	Vaccines	Other medicines
€5.2 bn	**€1.3 bn**	**€1.1 bn**	**€4.0 bn**

sanofi

Q2 2026 *Results*

Sales by Geography

US	Europe	Rest of the World
€6.3 bn	**€2.1 bn**	**€3.1 bn**

Pipeline Progress

- **7** regulatory approvals, in immunology, rare diseases, oncology, and neurology
- **2** positive phase 3 readouts in rare diseases and immunology
- **4** regulatory submission acceptances in the US, Europe, and Japan

Sustainability

The Impact® medicines portfolio is now available in **30 underserved countries**, supporting the Global Health Unit's goal of reaching two million patients with non-communicable disease treatments by 2030.

For further information on Q2 2026 results and definitions of financial indicators, please refer to the press release issued on July 30, 2026 at: www.sanofi.com/en/investors

sanofi